GSK Pharma Q1 net profit up 35 percent at Rs 113 crore in FY20
Mumbai: GlaxoSmithKline (GSK) Pharmaceuticals on Monday announced a 35 per cent jump in its net profit to Rs 113.5 crore during the first quarter of current fiscal from Rs 88.6 crore in the corresponding quarter ended June 30 last year.
The total income also rose by 7 per cent to Rs 818 crore as against Rs 753 crore in the same period. At the same time, total expenses increased from Rs 607 crore to Rs 642 crore.
Read Also: GSK to appoint Novartis, Astrazeneca ex-executive Jonathan Symonds as new Chairman: Bloomberg
Profit before tax in Q1 FY20 was Rs 176 crore compared to Rs 138 crore in Q1 of FY19, the company said in a statement.
The earnings per share of Rs 10 each works out to Rs 6.70 in the quarter ended June 30 compared to Rs 5.23 in the first quarter of the previous year.
Read Also: GSK drug Zejula helps ovarian cancer patients live longer in late-stage study
GlaxoSmithKline Pharmaceuticals business has been serving healthcare needs in India for more than 90 years. It has a wide range of prescription medicines across areas covering anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases.
Read Also: GSK to fund doctoral programs at Government established Regional Centre for Biotechnology
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd